Recipharm, a CDMO, has partnered with Aptahem, biotechnology company, for the formulation of Apta-1 drug candidate.   The aptamer-based drug candidate is intended to treat life-threatening condition sepsis, a potentially fatal condition which involves a general inflammatory response, known as systemic inflammatory response syndrome (SIRS), caused by an infection.   Recipharm will develop an injectable formulation for the upcoming Phase I study.     The partnership follows the positive resu...